Section Review: Oncologic, Endocrine & Metabolic: Drugs in development for the treatment of metabolic bone disease

References

• RAISZ L: Local and systemic factors in the pathogenesis of osteoporosis. New Engl. J. Med. (1988) 318:818–828.
   PubMed Web of Science ®Google Scholar
• KANIS JA: Pathology and treatment of Paget's disease of bone. Martin Dunitz, London (1991). An excellent overview of all aspects of Paget's disease.
   Google Scholar
• KANIS JA, O'ROURKE N, MCCLOS1CY EV: Consequences of neoplasma induced bone resorption and the use of clodronate [Review]. Int.J. Oncol. (1994) 5:713–731.
   PubMed Web of Science ®Google Scholar
• FLEISCH H: Bisphosphonates: pharmacology and use in the treatment of tumour induced hypercalcaemia and metastatic bone disease. Drugs (1991) 42(6):919–944.
   PubMed Web of Science ®Google Scholar
• BODY J.J: Bone metastases and tumour-induced hyper-calcaernia. Curr. Optn. Oncol (1992) 4:624–631.
   PubMedGoogle Scholar
• RIGSS BL, MELTON LJ: The prevention and treatment of osteoporosis. New Engl. J. Med. (1992) 327:620–627.
   PubMed Web of Science ®Google Scholar
• BARRET-CONNOR E, BUSH TL: Estrogen and coronary heart disease in women. J. Am, Med. Assoc. (1991) 265:1861–1867.
   Web of Science ®Google Scholar
• LOBO RA: Benefits and risks of estrogen replacement treatment. Am. J. Obstet. Gynaecol. (1995) 173:982–989.
   PubMed Web of Science ®Google Scholar
• VAN DER VIES J: Pharmacological studies with OD 14.Maturitas (1987) 1(Suppl.):15–24.
   Google Scholar
• GENNAZZANI AR, BENEDEK-JASZMAN LJ, HART DM, AN-DOLESK L, KICOVIC PM, TAX L: Org OD 14 and the endometrium. Maturitas (1991) 13(3):243–251.
   PubMed Web of Science ®Google Scholar
• RYMER J, CHAPMAN MG, FOGELMAN I: Effect of tiboloneon postmenopausal bone loss. Osteoporosis Int. (1994) 4:314–319.
   PubMed Web of Science ®Google Scholar
• LINDAY R, MCK HART D, KRASZEWSKI A: Prospectivedouble-blind trial of synthetic steroid (Org OD 14) for preventing postmenopausal osteoporosis. Br. Med. J. (1980) 1:1207–1209.
   Google Scholar
• GEUSENS P, EEQUEKER J, GIELEN J, SCHOT LP: Non-linear Increase in vertebral density induced by a synthetic steroid (Org OD 14) in women with established osteoporosis. Maturitas (1991) 13:155–162.
   PubMed Web of Science ®Google Scholar
• WRIGHT CDP, COMPSTON JE: Tamoxifen: oestrogen or anti-oestrogen in bone. QJM (1995) 88:307-310. A comprehensive review of the effects of tamoxifen on bone.
   Google Scholar
• TURNER TR, WAKELY GK, HANNON KS, BELL NH: Ta-moxifen prevents the skeletal effects of ovarian defi-dency in rats. J. Bone Mineral Res. (1987) 2:449–456.
   PubMed Web of Science ®Google Scholar
• TURNER TR, WAKELY GK, HANNON KS, BELL NH: Ta-moxifen inhibits osteodast mediated resorption of trabecular bone in ovarian-hormone defident rats. Endocrinology (1988) 122:1146–1150.
   PubMed Web of Science ®Google Scholar
• JORDAN VC, PHELPS E, LINDGRE JU: Effects of antiestro-gem on bone in castrated and intact female rats. Breast Cancer Res. Treat. (1987) 10:31–35.
   PubMed Web of Science ®Google Scholar
• LOVE RR, MAZESS RB, BARDENS HS, EPSTEIN S, NEW-COMB PA, HORDAN VC, CARBONNE PP, DEMETS DL: Effects of tamoxifen on uterus and ovaries of post-menopausal women in a randomised breast cancer prevention triaL New Engl. J. Med. (1992) 326:852–856.
   Google Scholar
• ISMAIL SM: Effect of tamoxifen on uterus. Lancet (1994)344:622–623.
   PubMedGoogle Scholar
• }CEDAR T, BOURNE TI-1, POWLES TJ, COLLINS WP, ASHLEYSE, COSGROVE DO, CAMPBELL S: Effect of tamoxifen on uterus and ovaries of postmenopausal women in a randomised breast cancer prevention triaL Lancet (1994) 343:1318–1321.
   Google Scholar
• JONES CD, SUAREZ T, MASSEY EH, BACK LJ, TINSLEY FC:Synthesis and anti-estrogenic activity of [3,4-dihydro-2- (4-methoxypheny1)-1-naphthalenyllE4-(2-pyrrolidinyl) -ethoxyj-phenyl]methanone, methanone sulphonic acid salt. J. Med. Chem. (1979) 22:962–966.
   PubMed Web of Science ®Google Scholar
• BLACK LJ, JONES CD, FACONE JR: Antagonism of estro-gen action with a new benzothiophene derived anties-trogen. Life Sci. (1983) 32:1031–1036.
   PubMed Web of Science ®Google Scholar
• BLACK LJ, SATO M, ROWLEY ER, MAGEE DE, BEKELE A,WILLIAMS DC, CULLINAN GJ, BENDELE R, KAUFFMAN RF, BENSCH WR, FROLIK CA, TERMINE JD, BRYANT FIU: Raloxifene (LY 139481 HCI) prevents bone loss and reduces serum cholesterol without causing uterine hy-pertrophy in ovariectomized rats. J. Clin. Investi. (1994) 93:63–69.
   PubMed Web of Science ®Google Scholar
• EVANS G, BRYANT HU, MAGEE D, SATO M, TURNER RT: The effects of raioxifene on tibia histomorphometry in ovariectomised rats. Endocrinology (1994) 135:2001–2005.
   PubMedGoogle Scholar
• TURNER CH, SATO M, BRYANT HU: Raloxifene preserves bone strength and bone mass in ovarectomised rats. J. Bone Mineral Res. (1994) 9:715–724.
   PubMedGoogle Scholar
• SATO M, MCCLINTOCK C, KIN G, TURNER CH, BRYANTHU, MAGEE D, SLEMENDA CW: Dual-energy X-ray ab-sorptiometry of raloxifene effects on the lumbar verte-brae and femora of ovarectoraised rats. J. Bone Mineral Res. (1994) 9:715–724.
   PubMed Web of Science ®Google Scholar
• EPPENBERGER U, WOSIKOWSKI K, KUNG W: Pharnaa-cologic and biologic properties of droloxffene, a new antiestrogen. Am. J. Clin. Oncol. (CCT) (1991) 14(Suppl 2):S5–S14.
   PubMedGoogle Scholar
• BIEDERMANN E, LOSER R, HASMANN MJ: Droloxifene isa more effective growth and protein synthesis inhibitor than tamoxifen and toremifene. J. Cancer Res. Clin. Oncol. (1992) 118(Suppl.):R172.
   Google Scholar
• KVINNSLAND S: Droloxifene, a new antiestrogen. Am.J.Clin. Oncol. (CCT) (1991) 14\(Suppl. 2):S45–S51.
   Google Scholar
• KE HZ, SIMMONS HA, PIRIE C, CRAWFORD DT, THOMPSON DD: Droloxifene, a new oestrogen antago-nist prevents bone loss in ovariectomised rats. Endocri-nology (1995) 136:2435–2441.
   PubMed Web of Science ®Google Scholar
• CHEN HK, DE HZ, JEE WSS, MA YF, PIRIE CM, SIMMONSHA, THOMPSON DD: Droloxifene prevents ovariec-tomy-induced bone loss in tibiae and femora of aged female rats: a dual-energy X-ray absorptiometric and histomorphometric study. J. Bone Mineral Res. (1995) 10:1256–1262.
   PubMed Web of Science ®Google Scholar
• DODWELL DJ, HOWELL A: The systemic treatment ofbone metastases. In: Bone Metastases. Rubens RD, Fogel-man I. (Eds.), Springer Verlag, London (1991): 121–147.
   Google Scholar
• BUXDAR AU, KAU S, HORTOBAGYI GN, THERLANET RL,BOOSER D, HOLMES FA, WALTERS R, KRAKOFF IH: Phase I trial of droloxifene in patients with metastatic breast cancer. Cancer Chemother, and Pharmacol. (1994) 33:313–316.
   PubMedGoogle Scholar
• RAUSCHING W, PRITCHARD KI: Droloxifene, a new an-tioestrogen: its role in metastatic breast cancer. Breast Cancer Res. Treat. (1994) 31:83–94.
   PubMed Web of Science ®Google Scholar
• COOMBES RC, HAYNES BP, DOWSETT M, QUIGLEY M, ENGLISH J, JUDSON IR, GRIGGS u, P011 ER GA, MCCAGUE R, JARMA M: Idoxifene; report of a Phase I study in patients with breast cancer. Br. J. Cancer (1994) 70:409–414.
   PubMedGoogle Scholar
• SIETSEMA WK, EBETINO FH: Bisphosphonates in devel-opment for metabolic bone disease. Exp. Opin. Invest. Drugs (1994) 3(12):1255–1276. Provides a good overview of the development of bisphosphonate compounds.
   Google Scholar
• CHESNUT CH, MCCLUNG MR, ENSRUD KE, BELL NH, GENANT HK, HARRIS ST, SINGER FR, STOCK/L, YOOD RA, DELMAS PD, KHER UN PRYOR-TILLOTSON S, SANTORA AC: Aledronate treatment of the postmenopausal osteoporotic woman: effect of multiple dosages on bone mass and remodelling. Am. J. Med. (1995) 99:144–152.
   PubMed Web of Science ®Google Scholar
• DOWNS R, BAKER M, BELL N, EMKEY R, TONINO R, TUCCIJ, WEISS S, PEVERLY C, KHER U, SANTORA A: Three year treatment of osteoporosis in postmenopausal women with oral alendronate: effects on bone mass and turn-over and safety. J. Bone Mineral. Res. (1995) 10\(Suppl. 1):S139.
   Google Scholar
• FRANCIS R: Oral bisphosphonates in the treatment of osteoporosis: a review. Curr. Ther. Res. (1995) 56:831–851.
   Web of Science ®Google Scholar
• LIBERMAN UA, WEISS SR, BROLL J, MINNE HW, QUAN H, BELL NH, RODRIGUEZ-PORTALES J, DOWNS RW, CAPIZZI T, SANTORA AC, LOMBARDI A, SHAH RV, HIRSCH LJ, KARPF DB: Effect of oral alendronate on bone mineral density and the incidence of fractures in post-menopausal women. New Engl. J. Med. (1995) 333:1437-1443. This paper provides information on the possibility that alendronate will decrease non-vertebral fractures.
   Google Scholar
• ARLOT MC, MEUNIER PJ, CHANASS1EUX P, RECKER R, REDA C, WEI L, YATES AJ: Effects of long-term alen-dronate treatment for post-menopausal osteoporosis on bone histomorphometry. J. Bone Mineral Res. (1995) 19\(Suppl. 1):5199.
   Google Scholar
• EISMAN JA, CHRISTIANSEN C, MCCLING M, GILCHRIST N, LUCKEY M, HALE E, REDA C, DAIFTOS A: Alendronate prevents bone loss in the spine and hip in recently postmenopausal women. J. Bone Mineral Res. (1995) 10\(Suppl. 1):S176.
   Google Scholar
• YATES AJ, MCCLUNG M, RAVN P, WASNICH R, HOSKING D, CAPIZZI T, DALEY M: EPIC: a 1609-subject osteoporosis prevention study. J. Bone Mineral Res. (1995) 10(Supp. 1):S254.
   Google Scholar
• MORTENSEN L, BEKKER P, VAN DER OUWELAND F, HOROWITZ Z, RUPICH R, DIGENNARO J, AXELROD D, CHARLES P, JOHNSTON C: Prevention of early post-menopausal bone loss by risedronat a two-year study. J. Bone Mineral Res. (1995)10\(Suppl. 1):S140.
   Google Scholar
• DELMAS PD, HARDOUIN C, CONFAVEREAUX, HARDY P, BREMOND A: Intermittent risedronate prevents bone loss in women with artificial menopause induced by chemotherapy of breast can. J. Bone Mineral Res. (1995) 10\(Suppl. 1):S200.
   Google Scholar
• ETTINGER B, GENANT H, BEKKER P, SHEN L, AXELROD D: A pilot three-year study of risedronate in women with breast cancer and chemotherapy-induced menopause. J. Bone Mineral Res. (1995) 10\(Suppl. 1):5198.
   Google Scholar
• LANGDAHL B, ERIKSEN EF, MORTENSEN P, CHARLES P, BEKKER PP, AXELROD D: Histomorphometry from a 36. three-year risedronate bone loss prevention study. J Bone Mineral Res (1995) 10(S1);S199.
   Google Scholar
• REGINSTER A, DEROISY R, NEDIS D et at.: Prevention of postmenopausal bone loss by Tiludronate. Lancet(1989) 2:1416–1471.
   Google Scholar
• REID IR, WAT1IE DJ, EVANS MC, GANBLE GD, STAPLETON JP, CORNISH J: Continuous therapy with pamidronate, a potent bisphosphonate in postmenopausal osteoporosis. J. Clin. Endocrinol. and Metabol. (1994) 79:1595–1599.
   PubMed Web of Science ®Google Scholar
• LUFKIN EG, ARGUETA R, WHITAICER MD, CAMERON AL, WONG VH, EGAN KS, FALLON WM, RIGGS BL: Pamidronatel and unrecognised problem in gastroin-testinal tolerability. Osteoporosis Int. (1994) 4:320–322.
   PubMed Web of Science ®Google Scholar
• O'DOHERTY D, MCCLOSKEY EV, VASIKARAN S, KHAN S, KANIS JA: The effects of intravenous akndronate in Paget's disease of bone. J. Bone Mineral Res. (1995) 10:1094–1100.
   PubMedGoogle Scholar
• RYAN W, BEKKER P: Long-term follow-up in Paget's patients treated with risedronate. J. Bone Mineral Res. (1995) 10:S1:5502.
   Google Scholar
• O'ROURKE NP, MCCLOSKEY EV, ROSINI S, COLEMAN RE, KANIS JA: Treatment of malignant hypercalcaemia with aminohexane bisphosphonate (neridronate). Br.J. Can-cer(1994) 69:914–917.
   PubMed Web of Science ®Google Scholar
• NODA M, CMILLIERE JJ, NUSSBAUM SR, WARRELL RP, RUDE R, GLUSMAN J, BILEZIKLAN JP, STEWART AF, STEPANAV-AGE M, SACCO JF, AVERBUCH SD, GERTZ BJ: Dose re-sponse study of alendronate sodium for the treatment of cancer associated hypercalcaemia. J. Clin. Oncol. (1993) 11:1618–1623.
   PubMed Web of Science ®Google Scholar
• FUKUMOTO S, MATSUMOTO T, TAKEBE K, ONAYA T, E'TO S, NAWAT H, OGATA E: Treatment of malignancy-asso-ciated hypercalcaetnia. with YM 175, a new bisphos-phonate: elevated threshold for parathyroid hormone secretion in hypercalcaemic patients. J. Clin. Endocrinol. Metabol. (1994) 79:165–170.
   Google Scholar
• RIZZOLI R, THIEBAUD, D, BUNDRED N, HERMANN Z, HUSS HJ, MANEGOLD C, TUBIANA-HULIN, STEINHAUER EU, CAPPELAERE P, THURLIMANN B, CLEMENS MR, EGH-BALI H, BODY JJ: Pathophysiology of malignant hyper-calcaemia in relation with serum parathyroid hormone-related protein levels and response to the bisphosphonate ibandronate. Bone (1995) 17:S75.
   Google Scholar
• PLOSKER GL, GOA KL: Clodronate. A review of its phar-macological properties and therapeutic efficacy in re-sorptive bone disease. Drugs (1994) 47:945-982. A comprehensive review of this compound.
   Google Scholar
• FITTON A, MCTAVISH D: Pamidronate. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease. Drugs (1991) 41:289-318. A comprehensive review of this compound.
   Google Scholar
• GLOVER D, LIPTON A, KELLER A, MILLER AA, BROWNINGS, FRAM RJ, GEORGE S, ZELENAKAS K, MACERATA RS, SEAMAN JJ: Intravenous pamidronate disodium treat-ment of bone metastases in patients with breast cancer. A dose seeking study. Cancer (1994) 74:2949–2955
   Google Scholar
• AZRIA M: In: The Calcitonins: Physiology and Pharmacology.Azria M (Ed.), Karger, Basle (1989).
   Google Scholar
• GENNARI C, AGNUSEDI D: Calcitonins and osteoporosis. Brit. J. Clin. Pract. (1994) 48:196–200.
   PubMedGoogle Scholar
• OVERGAARD K, RIIS BJ: Nasal calcitonin in osteoporosis. Calcified Tissue Int. (1994) 55:79–81.
   PubMed Web of Science ®Google Scholar
• REGINSTER JL: Treatment of bone in elderly subjects: calcium, vitamin D, fluor, bisphosphonates, calcitonin. Hormone Research (1955) 43:83–88.
   Google Scholar
• ANONYMOUS: Cortecs oral delivery of salmon cal&tonin to go with phase II trials for osteoporosis and Paget's Disease. Cortecs International Press Release (May 18 1994).
   Google Scholar
• CHAPUY MC, ARLOT MC, DUBOEF F, BRUN J, CROUZAET B, ARNAUD S, DELMAS PD, MEUNIER PJ: Vitamin D3 and calcium to prevent hip fractures in elderly women. New Engl. J. Med. (1992) 327:1637–1642.
   PubMed Web of Science ®Google Scholar
• CHAPUY, MC, ARLOT ME, DELMAS PD, MEUNIER PJ: Effect of calcium and cholecakiferol treatment for three yearson hip fractures in elderly women. Brit. Med. J. (1994) 308:1081-1082. A pivotal study demonstrating that calcium and cholecakiferol can reduce hip fractures.
   Google Scholar
• COMPSTON JE: The role of vitamin D and calcium supplementation in prevention of osteoporosis frac-tures in the elderly. Clin. Endocrinol. (1995) 43:393–405.
   PubMed Web of Science ®Google Scholar
• HAVSTEEN B: Flavenoids, a class of natural products ofhigh pharmacological potency. Biochem. Pharmacol. (1983) 32:1141–1148.
   PubMed Web of Science ®Google Scholar
• BRAND! ML: Flavenoids: biochemical effects and thera-peutic applications. Bone & Mineral (1992) S3;S3–S14.
   Google Scholar
• BRAND! ML: New treatment strategies: ipriflavone,strontium, vitamin D metabolites and analogues. Am. J. Med. (1993)95 (S5A):69S–74S.
   Google Scholar
• REGINSTER JL: Ipriflavone: pharmacological propertiesand usefulness in postmenopausal osteoporosis. Bone & Mineral (1993) 23:223–232.
   PubMedGoogle Scholar
• BONUCCI E, SILVESTRINI G, BALLANTI P, MASI L, FRANCH1A, BUFALINO L, BRANDI ML: Cytological and ultrastruc-tural investigation on osteoblastic and preosteoblastic cells grown in vitro in the presence of ipriflavone: preliminary results. Bone & Mineral (1992) 19:515–525.
   Google Scholar
• CHENG S-L, ZHANG S-F, NELSON TL, WARLOW PM, ovum,'" R: Stimulation of human osteoblast differen-tiation and function by ipriflavone and its metabolites. Calcified Tissue Int. (1994) 55:356–362.
   PubMed Web of Science ®Google Scholar
• FUJITA T, ONO K, INOHOE T, TORIZUKA K, SHIMZU A,MORE! H, OHHATA M, MUZONO K, TAKAHASHI H, YOSH-IOKA Y, YOSHIMOTO Y, TAKAOKA K, FUKUCHI M, MORITA R, KONNO T, HANYU T: Dose-finding study on TC-80 (ipriflavone) in osteoporosis. Prog. Med. (1985) 5:2959–2971.
   Google Scholar
• KOVACS AB: Efficacy of ipriflavone in the preventionand treatment of postmenopausal osteoporosis. Agents & Actions (1994) 41:86–87.
   PubMedGoogle Scholar
• VALENTE M, BUFALINO L, CASTILIONE GN, D'ANGELO R,MANCUSO A, GALOPPI P, ZICHELLA L: Effects of 1-year treatment with ipriflavone. Calcified Tissue Int. (1994) 54:377–380.
   PubMed Web of Science ®Google Scholar
• GAMBACCIANI M, SPINET A, CAPPAGLI B, TAPONECO F,FELLPETTO R, PARRINI D, CAPPELLI N, FIOREITI P: Effects of ipriflavone administration on bone mass and meta-bolism in ovariectomised women. J. Endocrinol. Invest. (1993) 16:333–337.
   PubMed Web of Science ®Google Scholar
• AGNUSDEID, CAMPOREALE A, GONNERLLI S, GENNARI C,BARONI MC, PASSEERI M: Short-term treatment of Paget's disease of bone with ipriflavone. Bone & Mineral (1992) 19:S35–S42.
   PubMedGoogle Scholar
• MARACHISO PC, CIRRILLO D, NALDINI L et al.: Cell sub-stratum of cultured avian osteoblasts is mediated by spedfic cell adhesion structures. J. Cell Biol. (1984) 99:1696. AUBIN JE: Osteodast adhesion and resorption: the role of podosomes. J. Bone Mineral Res. (1992) 7:365. OURSLER MJ, SPELSBERG TC: Echistatin: a potential new drug for osteoporosis. Endocrinology (1993) 132:939. HEWISON M: New trends in bone research. J. Royal Coll. Phys. Lon. (1995) 29:383-387. SATO M, GARSKY V, MAJESKA RJ, EINHORN TA, MURARAY J, TASHJIAN AH, GOULD RJ: Structure activity studies of the s-echistatin inhibition of bone resorption. J. Bone Mineral Res. (1994) 9:1441–1449.
   Google Scholar
• PITINER RA, ALBRANDT K, BEAUMONT K, GAETA LS, KODA VE, MOORE C, RI! IENHOUSE J, RINK TJ: Molecular physiology of amylin. J. Cell. Biochem. (1994) 55:S19–S28.
   Google Scholar
• COOPER GJC: Asnylin compared with caldtonln gene-related peptide; structure, biology and relevance to metabolic diseases. Endocrine Rev. (1994) 15163.
   Google Scholar
• CORNISH J, CALLON KR, COOPER GJ, REID IR: Biochem. Biophys. Res. Comm. (1995) 207:133–139.
   PubMedGoogle Scholar
• VAANANEN HK, KARHUKORPI EK, SUNDQUIST K, WALL-MARK B, ROININEN I, HENTUNEN T, TUUKKANEN J, LAKKAKORPI P: Evidence for the presence of a proton pump of the vacuolar HtATPAase type in the ruffled border of osteoclasts. J. Cell. Biol. (1990) 111:1305–1311.
   PubMed Web of Science ®Google Scholar
• DAVID P, BARON R: The vacuolar 11+-ATPAse: a potential target for drug development in bone diseases. Exp. Opin. Invest Drugs (1995) 4(8):725–740.
   Google Scholar
• RINGE JD, NEUNIER PJ: What is the future for fluoride in the treatment of osteoporosis? Osteoporosis Int. (1995) 5:71–74.
   Google Scholar
• RIGGS BL, HODGSON SF, O'FALLON WM, CHAO EYS, WAHNER HW, MUHS JM, CEDEL SL, MELTON LJ: Effect of fluoride treatment on the fracture rate in post-menopausal women with osteoporosis. New Engl .J. Med. (1990) 322:802–809.
   PubMed Web of Science ®Google Scholar
• KLEEREKOPER M, PETERSON EL, NELSON DA, PHILIPS E, SCHORK MA, TILLEY BC et al.: A randomised trial of sodium fluoride as a treatment of postmenopausal osteoporosis. Osteoporosis Int. (1991) 1155–161.
   Google Scholar
• PITT P, BERRY H: Fluoride treatment in osteoporosis. Postgrad. Med. J. (1991) 67:323–326.
   PubMed Web of Science ®Google Scholar
• SEYMOUR DG, DAY JJ, PATHY MSJ: Sodium fluoride: too late and too toxic for the elderly osteoporosis patient? Age and Ageing (1990) 19:222–228.
   PubMed Web of Science ®Google Scholar
• RIGGS BL, O'FALLON WM, LANE A, HODGSON SF, WAHNER HW, MUHS JM et al.: Clinical trial of fluoride therapy in postmenopausal osteoporotic women: ex-tended observations and additional analysis. J. Bone Mineral Res. (1994) 9:265–275.
   Google Scholar
• PAK CYC, SAKHAEE K, ADAMS-HURT B, PIZIAK V, PETER-SON RD, POINTDEXZTER JR: Treatment of post-menopausal osteoporosis with slow-release fluoride. Ann. Internal Med. (1995) 123401–409. A relatively small but well executed trial which suggests that fluoride is still a potential treatment in osteoporosis.
   Google Scholar
• MOHAN S, BAYLINK DJ: Bone formation factors. Clin. Orthop. Rel. Res. (1991) 263:30–48.
   PubMedGoogle Scholar
• SCHMID C: IGEs: function and clinical importance 2. The regulation of osteoblast function by hormones and cytokines with spedal reference to insulin-like growth factors and their binding proteins. J. Internal Med. (1993) 234:535–542.
   Google Scholar
• MOCHIZUKIH, HAKEDA Y, EWAKATSUKI N, USIU,N, AKASHI S, SATO T, TANAKA K, KUMEGA M: Insulin-like growth factor I supports formation and activation of osteoclasts. J. Endocrinol. (1992) 131:1075–1080.
   Google Scholar
• SLOOTWED MC, MOST WW, VAN BEEK E,SCHOT LPC, PAPAPOULOS SE, LOWIK CWGM: Osteoblast formation together with interieukin-6 production in mouse long bones is increased by insulin-like growth factor-L J. Endocrinol. (1992) 132:433–438.
   Google Scholar
• CENTRELLA M, HOROWITZ MC, WOZNEY J, MCCARTHY TL: Transforming growth factor-beta gene family mem-bers and bone Endocrine Rev. (1994) 15:27–39.
   Google Scholar
• CENTRELLA M, MCCARTHY TL, CANALIS E: Transforming growth factor beta and remodelling of bone. J. BoneJoint Surgery Am. Vol. (1991) 73:1418–1428.
   PubMed Web of Science ®Google Scholar
• WEMEAU JL: Calciotropic hormones and ageing. Hor-mone Res. (1995) 4376–79.
   Google Scholar
• ROSEN CJ: Growth hormone, insulin-like growth factors and the senescent skeleton: Ponce de Leon's fountain revisited J. Cell. Biochem. (1994) 56:348–356.
   PubMed Web of Science ®Google Scholar
• NICOLAS V, MOHAN S, HONDA Y, PREWEIT A, FINKEL-MAN RD, BAYLINK DJ, FARLEY: An age-related decrease In the concentration of insulin-like growth factor bind-ing protein-5 in human cortical bone (1995) 57:206–212.
   Google Scholar
• BENNETT AE, WAHNER HW, RIGGS BL, HINTX RI: Insu-lin-like growth factors land II: ageing and bone density in women. J. Clin. Endocrinol. Metabol. (1984) 59:701–704.
   PubMed Web of Science ®Google Scholar
• LJUNGHALL S, JOHANSSON AG, BURMAN P, KAMPE 0, LINDH E, KARLSSON FA: Low plasma levels of insulin-like growth factor I (IGF-I) in male patients with idi-opathic osteoporosis. J. Int. Med. (1992) 232:59–64.
   PubMed Web of Science ®Google Scholar
• REED BY, ZERAXTEKH HJE, SAKHAEE K, BRELAU NA, GOTTSHALK F PAK CYC: Serum IGF I is low and corre-lated with osteoblastic surface in idiopathic osteoporosis. J. Bone Mineral. Res. (1995) 10:1218–1224.
   PubMed Web of Science ®Google Scholar
• EBELIG PR, HONES JD, O'FALLON WM, HANES CH, RIGGS BL: Short-term effects of recombinant human insulin-like growth factor II on bone turnover in normal women. J. Clin. Endocrin. Metabol. (1993) 771384–1387.
   Google Scholar
• JOHANSSON AG, LINDH E, LJUNGHALL S: Insulin-like growth factor I stimulates bone turnover in osteoporosis. Lancet (1992) 339:1619. 95. so
   Google Scholar
• RUBIN CD, REID B, SAKHAEEK K, PAK CYC: Treating a patient with the Werner syndrome and osteoporosis using recombinant human insulin growth factor. Ann. Internal Med. (1994) 121: 665–669.
   PubMed Web of Science ®Google Scholar
• TURNER CH: Toward a cure for osteoporosis: reversal of excessive bone fragility. Calcified Tissue Int. (1991) 2:12–19.
   Google Scholar
• JOHANSSON AG, LINDH E, LJUNGHALL S: Growth hor-mone, insulin-like growth factor I and bone: a clinical review. J. Internal Med. (1993) 234:553–560.
   Google Scholar
• INZUCCHI SE, ROBBINS RI Effects of growth hormone on human bone biology. J. Clin. Endocrinol. Metabol. (1994) 79:691–694.
   PubMed Web of Science ®Google Scholar
• RUDMAN D, FELLER AG, NAGRAJ HS, GERGANS GA, LALITHA PY, GOLDBERG AF et al.: Effects of human growth hormone in men over 60 years old. New Engl. Med. (1990) 323:1–6.
   PubMed Web of Science ®Google Scholar
• HOLLOWAY L, KOHLMEIER L, MARCUS R: Effects of cyclic recombinant human growth hormone and salmon cal-citonin on bone mineral density and bone turnover in postmenopausal women. J. Bone Mineral Res. (1995) 10(S1):S253.
   Google Scholar
• DEMPSTER DW, COSMAN, PARSIEN M, SHEN V, LINDSAY R: Anabolic actions of parathyroid hormone on bone. Endocrine Rev. (1993) 14:690–709.
   PubMed Web of Science ®Google Scholar
• DEMPSTER DW, COSMAN, PARISEN M, SHEN V, LINDSAY R: Anabolic actions of parathyroid hormone on bone: Update 1995. Endocrine Rev. (1995) 4:247–250.
   Google Scholar
• ANONYMOUS: Glaxo Holdings plc: Annual Report (1994).
   Google Scholar
• ANONYMOUS: Chugai: Annual Report (1993).
   Google Scholar
• BROWN EM, GANBA G, RICCARDI D, LOMBARD M et al.: Cloning and characterisation of an extracellular Ca2+-sensing receptor from bovine parathyroid. Nature (1993) 366:575–580.
   PubMed Web of Science ®Google Scholar
• TSURUKAMI H, NAKAMURA T, SUZUKI K, SATO K, HIGUCHI Y, NISHI Y: A novel synthetic vitamin D ana-logue, 2b-(3-hydoxypropoxyl) la, 25-dihydroxyvi-tatnin 1)3 (ED-71) increases bone mass by stimulating the bone formation in normal and ovariectomised rats. Calcified Tissue Int. (1994)54:142–149.
   PubMed Web of Science ®Google Scholar
• GROSFIELD JL, RESCORLA EJ, WEST KW, VANE DW: J. Sci. Ind. Res. (India) (1992) 51:341–343.
   Web of Science ®Google Scholar
• ANONYMOUS: Scotia Holdings plc: Interim Statement for the d6 months ended 30 June 1994. Annual Report (1994).
   Google Scholar
• ANONYMOUS: Scotia Holdings plc: Spring Research Review. Company Communication (28th April 1995).
   Google Scholar
• ANONYMOUS: Licensing Information. Suitomo Pharma-ceuticals Company communication (15th November 1994).
   Google Scholar
• BRANDI ML: New treatment strategies: ipriflavone, stroniu.m, vitamin D metabolites and analogues. Am. Med. (1993) 95:(S5A):69S–74S.
   Google Scholar
• MARIE PJ, HOTT M, MODROWSKI D, DE POLLAK C, GUILLEMEIN J, DELOFFRE P, TSOUDEROS Y: An uncou-pling agent containing strontium prevents bone loss by depressing bone resorption and maintaining bone for-mation in estrogen-deficient rats. J. Bone Mineral Res. (1993) 8:607–615.
   PubMed Web of Science ®Google Scholar